Antibody Ingredients TRIZ Cases

By binding the extracellular region of PTK7, neutralizing antibodies bypass active-site limits and inhibit tumor growth, migration, and angiogenesis.

By blocking PAPPA cleavage of IGFBP-2, -4, and -5, these binding proteins curb ADPKD cyst growth while avoiding tolvaptan liver concerns.

Fully human anti-NPR1 antibodies block receptor signaling to raise blood pressure for up to 28 days with less frequent dosing.

Specific CDR-engineered single-domain CTLA4 antibodies improve binding, block CD80/CD86 interaction, and boost T-cell anti-tumor activity.

Engineered anti-CD45 ADCs deplete endogenous CD45+ cells while reducing Fc-driven immune activation to support stem cell engraftment.

Dual-target CD19/CD38 antibodies deplete immunosuppressive B cells, promote apoptosis, and reduce cytokine release with fewer side effects.

CD163-targeting antibodies selectively modulate M2 macrophages to relieve tumor immunosuppression and boost cytotoxic T-cell activity.

Bispecific anti-Vβ17 antibodies selectively modulate T cells and redirect them to cancer targets while limiting broad immune effects.

Targeting Clec12A on myeloid cells enables antibodies to trigger ADCC, induce apoptosis, and inhibit leukemia cell proliferation.

High-affinity FZD5-binding antibody regions enable selective screening and growth inhibition of RNF43-mutant pancreatic cancer cells.

Bispecific CD3-CD20 binding redirects T cells to kill CD20-expressing tumor cells when standard anti-CD20 therapy shows resistance.

Engineered antibodies bind canine CD20 epitopes to deplete B cell lymphoma cells where human CD20 antibodies lack affinity.

Engineered CCR8-binding antibodies use CDR and Fc modifications to boost ADCC and CDC against tumor regulatory T cells in cancer.

Bispecific antibodies target HLA-A2/MAGE-A4 and CD3 to activate T cells while reducing MHC cross-reactivity and off-target toxicity.

An IgG4 anti-SIRPα antibody blocks CD47 signaling while minimizing ADCC and ADCP, improving tumor immune response with lower self-attack risk.

Specific CDR-sequence anti-PD-1 antibodies raise T cell activation by blocking PD-1/PD-L1 while addressing response limits and autoimmune risk.

CD7-binding antibodies drive cytotoxicity and phagocytosis to deplete relapsed T-ALL and other CD7-expressing cells.

Selective binding to CCR8 extracellular loop 2 targets suppressive Tregs without blocking CCL1, helping strengthen antitumor immunity.

Engineered VISTA-binding molecules reduce FcR-driven limits and immunogenicity while boosting CD8+ T cells and remodeling the tumor microenvironment.

PCSK9 antibody therapy adds LDL-C lowering beyond statins to cut residual cardiovascular risk after acute coronary syndrome.

Blocking CD39 with specific antibodies prevents ATP and ADP hydrolysis, reactivates T cells, and helps counter tumor immune escape.

Dual binding to TRAILR2 and CDH17 drives apoptosis in cancer cells while limiting hepatocyte toxicity and off-target activation.

By blocking the TFPI K2 region, this antibody boosts FXa and thrombin generation to reduce infusion frequency in coagulation disorders.

Combining PD-1/PD-L1 blockade with Resiquimod-driven dendritic and NK cell activation helps sustain tumor inhibition beyond antibody-only therapy.

A pH-dependent TFPI antibody restores coagulation while extending half-life, reducing infusion frequency for bleeding disorders.

High-affinity PD-L1 antibody variants use distinct CDR sequences to block PD-L1-PD-1 binding and strengthen T-cell antitumor activity.

Targeted ITGA2-binding antibodies linked to cytotoxic drugs improve tumor killing while limiting the toxicity of systemic chemotherapy.

DHODH inhibition with brequinar redirects myeloid precursors away from MDSCs, improving checkpoint immunotherapy in solid cancers.

A single-domain antibody targets CLDN18.2 ECD1 without binding CLDN18.1, improving selectivity, stability, and therapeutic use.

CDR grafting onto human antibody frameworks preserves TfR1 binding while improving solubility, thermal stability, and lower immunogenicity.

Monoclonal antibodies block LILRB2 signaling in myeloid cells to restore anti-tumor immunity in leukemia, myeloma, and solid tumors.

Selective antibodies against glycosylated LAG3 block suppressive ligand binding and restore T-cell cytokine release in tumors.

Epitope-specific monoclonal antibodies bind opioids in circulation to block brain distribution and help prevent or reverse overdose.

An Fc-fused ETAR extracellular antigen enables manufacturable antibody binding and stable formulation for PAH and reproductive organ cancers.

Highly specific GPC3 antibodies improve cancer targeting by enhancing T cell responses while limiting off-target effects in diagnosis and therapy.

Combining anti-PD-1 and anti-CTLA-4 antibodies addresses NSCLC chemoresistance and improves durable antitumor responses.

Affinity-matured humanized antibodies selectively bind NRP2 to block ligand interactions and modulate disease-linked signaling pathways.

Dual PSMA-STEAP1 DVD-Ig conjugates improve tumor coverage and internalization, helping address resistance in metastatic prostate cancer.

Multivalent anti-CD40 constructs raise intrinsic agonism without FcγR binding, avoiding receptor limits and unwanted effector functions.

Localized CD25-IR700 activation by near-infrared light depletes tumor Tregs while sparing non-target immune cells and limiting systemic toxicity.

Bispecific anti-STEAP2 and CD3 antibodies target STEAP2-expressing tumor cells, trigger T cell killing, and support prostate cancer therapy.

Combining CBM588 with a tyrosine kinase inhibitor enhances antitumor effects, reduces tumor volume, and improves survival rates.

Bcl-xL inhibitor payloads in anti-EGFR ADCs improve EGFRvIII-targeted cancer delivery while reducing ocular toxicity and infusion reactions.

A fully human IgG1 anti-CD20 antibody reduces HAMA/HACA risk while preserving strong ADCC and CDC activity for chronic treatment.

Adding Clostridium butyricum to anti-cancer immunotherapy helps restore beneficial gut bacteria and improve response in metastatic cancer.

Blocking MAdCAM-α4β7 binding reduces colitis and diarrhea during checkpoint therapy while preserving anticancer immune efficacy.

Single-domain antibodies improve PD-L1 binding and PD-1 blocking to boost T cell activation and anti-tumor response in more patients.

Targeted CDR sequence changes reduce deamidation hotspots while boosting CD19 affinity and cross-reactivity for B-cell and autoimmune therapy.

Bispecific CD38-CD28 antibodies deplete CD38+ tumor and suppressor cells while enabling controlled T-cell activation for relapsed cancers.

Dual-target binding drives tumor phagocytosis while limiting red blood cell binding.

This case combines atezolizumab with platinum chemotherapy and PD-L1 testing to extend survival in advanced urothelial carcinoma.

Non-neutralizing PfRH5 antibodies potentiate neutralizing antibodies to reduce red blood cell invasion by malaria merozoites.

This case uses histamine and HRH1 signaling to guide checkpoint inhibitor selection and alternative treatment decisions.

CCR8-specific antibodies block CCL1/CCR8 signaling and trigger ADCC to deplete immunosuppressive Tregs.

Notch4 antibodies target Th2 signaling to reduce airway inflammation selectively.

Targeting TRPV6 extracellular loops enables antibody access, channel modulation, cancer-cell apoptosis, and tissue-based disease detection.

Antibodies target KLRG1’s extracellular domain to block ligand binding and enhance CD8+ T and NK cell cytotoxicity.

This case shows how covalent antibody crosslinking boosts antigen binding and internalization while enabling greater payload delivery.

This regimen combines Compound 1 with retifanlimab to activate cytokines and enhance tumor growth inhibition.

This case combines CD40 stimulation with PD-1 blockade to activate APCs, strengthen antitumor immunity, and address treatment resistance.

pH-selective HSA binding extends therapeutic half-life while preserving tissue penetration.

A multispecific antibody lacking an immunoglobulin Fc region engages tumor cells and T-cells simultaneously to achieve high on-target potency.

Multiple doses of humanized anti-αβTCR antibodies reduce alpha beta T cells while preserving gamma delta T cells, lowering toxicity and infection risks.

S239D and I332E mutations in the Fc region of anti-FLT3 antibodies resolve low affinity for FcγRIIIa receptor, enabling effective cell killing in leukemia.

Merges CD137 activation with PD-1 blockade to boost anti-tumor immunity while managing hepatotoxicity risks from monotherapy.

PD1-H944 humanized antibody overcomes limited efficacy and safety of existing PD-1 inhibitors by blocking PD-L1/PD-L2 binding to reactivate T cells.

Heterobifunctional molecules link target proteins with exogenous antibodies to deplete pathogenic cells while improving therapeutic selectivity.

Novel monoclonal antibodies target CLDN18.2 without cross-reacting with CLDN18.1, enabling specific detection and treatment of gastric tumors.

Masking moieties conceal CD3 binding sites on bispecific molecules, preventing systemic toxicity by restricting T cell activation to tumor microenvironments.

Amino acid substitutions at positions 40 and 43 prevent proteolytic cleavage of GITR antibodies, maintaining binding affinity and therapeutic efficacy.

A humanized antibody-drug conjugate targets Claudin18.2-positive tumors with high affinity using a cytotoxic linker.

Segmented CAPRIN-1 antibodies target cancer cells specifically, reducing side effects on normal tissues.

Nidogen 1 targeting antibodies block pre-metastatic niche formation and angiogenesis to diminish lung metastasis.

Radioimmunoconjugates upregulate CD20 antigen expression to overcome treatment resistance from antigen drift.

Engineered anti-PRLR antibodies bind human prolactin receptors to block signaling and kill tumor cells.

Monovalent bispecific antibodies merge checkpoint blockade with costimulation to boost T cell activation while reducing peripheral toxicity.

A pharmaceutical combination activates innate and adaptive immunity to eliminate advanced subcutaneous tumors.

A bottle opener antibody format uses distinct heavy and light chain configurations to achieve monovalent binding of SSTR2 and CD3 antigens.

Disulfide-linked Fab conjugates restore divalent binding to MUC1 while preserving rapid renal clearance, resolving the trade-off between half-life and affinity.

Siglec ligand conjugates bind specific immune receptors to prevent neutralizing antibody formation, extending therapeutic durability.